Premium
Unilateral unifocal advanced intraocular retinoblastoma: is reasonable to adopt intra‐arterial chemotherapy as single therapeutic choice?
Author(s) -
De Francesco Sonia,
Leonini Sara,
Galluzzi Paolo,
Bracco Sandra,
Gennari Paola,
Maria Pinto Anna,
Neri Giovanni,
Barchitta Matteo,
Renieri Alessandra,
Hadjistilianou Doris
Publication year - 2019
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2019.5473
Subject(s) - retinoblastoma , medicine , chemotherapy , surgery , biochemistry , chemistry , gene
Purpose To report the outcome of 30 naive unilateral unifocal retinoblastoma cases treated with intra‐arterial chemotherapy alone. Methods From 2008 to 2019, 192 eyes affected with retinoblastoma have been treated with intra‐arterial chemotherapy (IAC). 100 out of 192 (52%) eyes were naive advanced unilateral unifocal retinoblastoma (Group B‐E). 30 out of 100 (30%) received intra‐arterial chemotherapy alone. All patients underwent genetic testing at diagnosis. MR was performed at diagnosis, during treatment (when necessary), 3 months after last infusion and annually to evaluate eyeball growth. Results Tumor control and globe salvage was achieved in 100% of the reported cases (follow‐up ranged from 11 years to 9 months). New tumors or relapse have not been detected. No further local or systemic therapies were necessary. Procedure complications and local and systemic effects are reported. No intraocular or orbital tumor recurrence or metastatic disease have been observed observed. Conclusions The outcome will be correlated to genetic analysis, doses and drugs used (alone or in combination) and number of infusions received.